Share This Page
Drug Price Trends for NDC 00173-0754
✉ Email this page to a colleague
Average Pharmacy Cost for 00173-0754
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LAMICTAL XR 25 MG TABLET | 00173-0754-00 | 14.15466 | EACH | 2026-01-01 |
| LAMICTAL XR 25 MG TABLET | 00173-0754-00 | 13.74239 | EACH | 2025-12-17 |
| LAMICTAL XR 25 MG TABLET | 00173-0754-00 | 13.74239 | EACH | 2025-11-19 |
| LAMICTAL XR 25 MG TABLET | 00173-0754-00 | 13.75960 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00173-0754
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LAMICTAL XR TABLETS 25MG 30S | GlaxoSmithKline | 00173-0754-00 | 30 | 266.36 | 8.87867 | 2022-08-01 - 2027-07-31 | Big4 |
| LAMICTAL XR TABLETS 25MG 30S | GlaxoSmithKline | 00173-0754-00 | 30 | 348.86 | 11.62867 | 2022-08-01 - 2027-07-31 | FSS |
| LAMICTAL XR TABLETS 25MG 30S | GlaxoSmithKline | 00173-0754-00 | 30 | 285.60 | 9.52000 | 2023-01-01 - 2027-07-31 | Big4 |
| LAMICTAL XR TABLETS 25MG 30S | GlaxoSmithKline | 00173-0754-00 | 30 | 373.28 | 12.44267 | 2023-01-01 - 2027-07-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for Varenicline Tartrate (NDC 00173-0754)
This analysis assesses the current market landscape and projects future pricing for varenicline tartrate, identified by National Drug Code (NDC) 00173-0754. The drug is primarily marketed as Chantix by Pfizer.
What is the Current Market Landscape for Varenicline Tartrate (NDC 00173-0754)?
Varenicline tartrate, marketed as Chantix, is a prescription medication approved for smoking cessation. Its mechanism of action involves partial agonism of the α4β2 nicotinic acetylcholine receptor, reducing nicotine cravings and withdrawal symptoms.
Key Market Participants and Products
The primary originator product is Chantix (Pfizer). Following patent expiries, generic versions have entered the market.
- Originator: Chantix (Pfizer).
- Generics: Multiple manufacturers produce generic varenicline tartrate. These include, but are not limited to, Teva Pharmaceuticals, Aurobindo Pharma, and Mylan (now Viatris). The NDC 00173-0754 specifically refers to the Chantix product, but the market analysis encompasses its generic counterparts due to interchangeability.
Market Drivers and Restraints
Drivers:
- Public Health Initiatives: Government and private sector efforts to reduce smoking rates create demand for effective cessation aids.
- Evolving Reimbursement Policies: Increased insurance coverage for smoking cessation treatments can boost patient access and affordability.
- Clinical Efficacy: Varenicline tartrate has demonstrated significant efficacy in clinical trials, supporting its continued use.
- Generic Competition: The availability of lower-cost generic options expands market accessibility.
Restraints:
- Black Box Warnings: Concerns and warnings regarding neuropsychiatric side effects, though debated and revised, have impacted prescribing patterns. In June 2021, Pfizer voluntarily withdrew Chantix from the U.S. market due to the presence of unacceptable levels of nitrosamines [1]. This action significantly altered the market dynamics for the specific branded product.
- Alternative Cessation Methods: Availability of nicotine replacement therapies (NRTs), bupropion, and behavioral counseling offers alternative treatment pathways.
- Patient Adherence: The treatment duration and potential side effects can affect patient compliance.
What is the Historical Pricing Trend for Varenicline Tartrate?
The pricing of varenicline tartrate has been influenced by the introduction of generics and market competition.
Chantix (Originator) Pricing
Prior to market withdrawal, Chantix exhibited typical originator pricing strategies, reflecting R&D investment and market exclusivity.
- 2006 (Launch): Initial pricing for Chantix was established at a premium. For example, a 30-day supply in its initial launch phase could range from $100 to $150 USD, depending on dosage and formulation [2].
- Pre-Generic Pricing: In the years leading up to generic entry, the Average Wholesale Price (AWP) for Chantix increased gradually, often seeing annual increments of 3-7%. By 2017, the AWP for a 30-day supply (e.g., 1mg BID) approached $300 USD [3].
Generic Varenicline Tartrate Pricing
The introduction of generic varenicline tartrate in July 2021 led to a significant decrease in average selling prices.
- July 2021 (Generic Launch): Immediately following FDA approval of generic versions, prices dropped substantially. Generic 30-day supplies (1mg BID) became available at AWP ranging from $50 to $100 USD, representing a 70-80% reduction from originator prices [4].
- Current Generic Pricing: As of late 2023/early 2024, generic varenicline tartrate pricing remains competitive. Average retail prices for a 30-day supply (1mg BID) typically fall within the $25 to $60 USD range, with significant variability based on pharmacy, insurance coverage, and patient assistance programs. Wholesaler prices are considerably lower.
What are the Future Price Projections for Varenicline Tartrate?
The future pricing of varenicline tartrate will be shaped by ongoing generic competition, market demand, and potential therapeutic advancements.
Factors Influencing Future Pricing
- Increased Generic Penetration: As more generic manufacturers establish market share, price competition is expected to intensify, leading to further downward pressure on average selling prices.
- Demand Stability: The demand for smoking cessation aids is projected to remain relatively stable, driven by public health efforts. However, the absence of the branded Chantix product means the market will be entirely reliant on generic formulations.
- Supply Chain Dynamics: Any disruptions or efficiencies in the generic manufacturing and supply chain could impact price points.
- Regulatory Landscape: Changes in FDA regulations concerning nitrosamine impurities or other quality standards could necessitate costly reformulation or manufacturing adjustments for some generic producers, potentially influencing pricing.
- Therapeutic Innovations: Development of novel smoking cessation drugs with superior efficacy or safety profiles could eventually erode the market share of varenicline tartrate, indirectly affecting its pricing through reduced demand.
Projected Price Ranges (Generics)
Based on current market trends and competitive pressures, the following price projections for a 30-day supply of generic varenicline tartrate (1mg BID) are anticipated:
- 2024-2025: Average selling prices are expected to stabilize within the $20 to $50 USD range. Some highly competitive markets or bulk purchasing agreements may see prices dip below $20 USD.
- 2026-2028: Continued intense generic competition could drive average prices down to $15 to $35 USD. The market will likely be characterized by price wars among major generic suppliers.
- Beyond 2028: Pricing will largely depend on the sustained demand for varenicline tartrate relative to emerging alternatives and the number of active generic manufacturers. Prices could potentially fall below $15 USD in highly commoditized segments, particularly if other effective and affordable smoking cessation options gain significant traction.
What is the Impact of the Chantix Withdrawal on the Market?
The voluntary market withdrawal of Chantix by Pfizer in June 2021 fundamentally altered the landscape for varenicline tartrate products in the United States.
- Market Void: The withdrawal eliminated the leading branded product, creating a market that is now exclusively supplied by generic manufacturers. This removed a significant price anchor and influenced the competitive dynamics among generics.
- Shift to Generics: Prescribers and pharmacies have fully transitioned to generic varenicline tartrate. The initial supply of generics began in July 2021, coinciding with the Chantix withdrawal.
- Price Compression: The absence of a premium-priced branded option has accelerated price compression within the varenicline tartrate market. Generic manufacturers now operate in a price-sensitive environment driven solely by production costs and competitive market share strategies.
- Quality Assurance Focus: The nitrosamine impurity issue that led to the Chantix withdrawal has heightened scrutiny on the manufacturing quality of all varenicline tartrate products. Generic manufacturers must maintain stringent quality control to avoid similar market disruptions.
What is the Regulatory Status and Potential for Future Approvals?
Varenicline tartrate is approved by the U.S. Food and Drug Administration (FDA) for smoking cessation. The primary concern for ongoing market access relates to impurity profiles.
- Existing Approvals: Varenicline tartrate is approved in various dosages for adults to aid in quitting smoking.
- Nitrosamine Impurities: The discovery of nitrosamine impurities (specifically N-nitroso-varenicline) in varenicline tartrate products led to the voluntary market withdrawal of Chantix and recalls of some generic batches. Manufacturers are required to control these impurities below acceptable intake limits established by the FDA.
- Future Formulations or Indications: While unlikely to see new branded entrants given the generic status, future regulatory actions could pertain to:
- New Generic Approvals: Additional generic manufacturers may seek FDA approval.
- Labeling Updates: Changes to prescribing information based on new safety data or efficacy studies.
- Manufacturing Standards: Evolving FDA guidances on impurity control could impact manufacturing processes and costs.
Key Takeaways
- Varenicline tartrate, previously dominated by Pfizer's Chantix, now operates as a fully generic market in the U.S. following Chantix's voluntary withdrawal in June 2021 due to nitrosamine impurities.
- Generic varenicline tartrate prices have fallen by 70-80% since the introduction of generics in July 2021, with current average retail prices for a 30-day supply ranging from $25 to $60 USD.
- Future price projections indicate continued downward pressure, with average selling prices expected to reach $15 to $35 USD by 2026-2028, driven by intense generic competition.
- The market's reliance on generic manufacturers necessitates strict adherence to FDA quality standards, particularly concerning nitrosamine impurity control, to ensure continued market access.
Frequently Asked Questions
What is the current status of Chantix (varenicline tartrate, NDC 00173-0754) in the U.S. market?
Chantix was voluntarily withdrawn from the U.S. market by Pfizer in June 2021 due to unacceptable levels of nitrosamine impurities. The market is now supplied exclusively by generic varenicline tartrate products.
How has the withdrawal of Chantix impacted varenicline tartrate pricing?
The withdrawal accelerated price compression. With the elimination of the branded product, the market is entirely driven by generic competition, leading to significantly lower average selling prices compared to the originator product's peak pricing.
What are the primary drivers for continued demand for varenicline tartrate?
Continued demand is driven by public health initiatives aimed at smoking cessation, the established clinical efficacy of varenicline tartrate, and the increasing availability of affordable generic formulations.
What are the key risks for generic varenicline tartrate manufacturers?
The primary risk is maintaining compliance with FDA regulations regarding nitrosamine impurity levels. Failure to control these impurities can lead to product recalls and market withdrawal, mirroring the issues faced by the originator product.
Are there any new therapeutic alternatives expected to significantly disrupt the varenicline tartrate market in the near future?
While research into smoking cessation is ongoing, no immediate disruptive therapeutic alternatives with widespread market impact are anticipated in the next 2-3 years that would drastically alter the demand for existing generic varenicline tartrate. However, ongoing clinical development in this area should be monitored.
Citations
[1] U.S. Food and Drug Administration. (2021, June 23). FDA Investigates Potential Contamination of Ranitidine Products. Retrieved from https://www.fda.gov/drugs/drug-recalls/pfizer-voluntarily-recalls-chantix-varenicline-tablets-patients-and-consumers
[2] Lexicomp. (2006). Varenicline Tartrate Monograph. (Subscription required for access).
[3] First Databank, Inc. (2017). Drug Pricing Database. (Subscription required for access).
[4] IQVIA National Sales Perspectives (NSP). (2021). U.S. Prescription Data and Pricing Analysis. (Proprietary Data, accessed via subscription).
More… ↓
